Last $59.06 USD
Change Today -0.39 / -0.66%
Volume 14.0M
ABBV On Other Exchanges
Symbol
Exchange
New York
EN Paris
Mexico
Frankfurt
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Open
$59.84
Previous Close
$59.45
Day High
$59.93
Day Low
$59.01
52 Week High
09/17/14 - $60.02
52 Week Low
09/27/13 - $44.02
Market Cap
94.1B
Average Volume 10 Days
11.1M
EPS TTM
$2.90
Shares Outstanding
1.6B
EX-Date
10/10/14
P/E TM
20.4x
Dividend
$1.68
Dividend Yield
2.78%
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. It has a strategic collaboration with Infinity Pharmaceuticals, Inc.; and a research and development collaboration with California Life Sciences LLC. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.

25,000 Employees
Last Reported Date: 08/7/14
Founded in 2012

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $790.0K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $710.0K
Executive Vice President of Business Developm...
Total Annual Compensation: $900.0K
Senior Vice President of Human Resources
Total Annual Compensation: $545.0K
Compensation as of Fiscal Year 2013.

abbvie inc (ABBV) Key Developments

Biogen Idec Inc. and AbbVie Inc. Announces Full Results from the Phase 3 Decide Clinical Trial

Biogen Idec and AbbVie announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis (RRMS) compared to AVONEX (interferon beta-1a). These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston. DECIDE was a two- to three-year, Phase 3, global, randomized, double-blind study that evaluated whether ZINBRYTA would provide superior outcomes for certain clinical endpoints compared to AVONEX. The study enrolled more than 1,800 patients with RRMS. Primary Endpoint: Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate (ARR) compared to patients treated with AVONEX (p<0.0001). Secondary Endpoints: ZINBRYTA demonstrated superiority in reducing the number of new or newly enlarging T2-hyperintense lesions at week 96, with a 54% reduction relative to AVONEX (p<0.0001). The risk of three-month confirmed disability progression, as measured by the Expanded Disability Status Scale (EDSS), was reduced by 16% in patients treated with ZINBRYTA compared to those on AVONEX (p=0.16). This was not statistically significant. 73% of ZINBRYTA patients were relapse-free compared to 59% of AVONEX patients (nominal p<0.0001) at week 96. The risk of meaningful worsening in the physical impact of multiple sclerosis (MS) (> 7.5 point worsening in the Multiple Sclerosis Impact Scale [MSIS-29] physical score) was reduced by 24% in the ZINBRYTA group compared to the AVONEX group (nominal p=0.018). The safety profile of ZINBRYTA in the DECIDE study was generally consistent with the Phase 2 studies. The overall incidence of adverse events was comparable across the ZINBRYTA and AVONEX treatment groups. In patients treated with ZINBRYTA compared to AVONEX, there was an increased incidence of serious infections (4% versus 2%). The pattern and types of infections seen in the ZINBRYTA group were consistent with what has been previously observed in the MS population. Also consistent with previous studies, patients in the ZINBRYTA group had a greater incidence of cutaneous adverse events and serious cutaneous reactions and elevations of liver transaminases greater than five times the upper limit of normal. There were four deaths in the AVONEX group and one death in the ZINBRYTA group, none of which was considered treatment related. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during the first half of 2015.

Federal Trade Commission Sues Abbvie and Teva over Generic AndroGel

The Federal Trade Commission is suing AbbVie and Teva, saying they conspired to temporarily keep generic versions of AbbVie's low-testosterone drug AndroGel off the market. The FTC says AbbVie Inc. and its partner and Besins Healthcare filed baseless patent infringement lawsuits against Teva Pharmaceutical Industries Ltd. and Perrigo Co. to delay the approval and sale of less-expensive generic versions of the drug. AbbVie then struck a deal with Teva that will allow Teva to sell a generic at a later date. The FTC says that agreement included payments to Teva the government alleges were illegal. The agency is asking a court to throw out the agreement between the companies.

AbbVie Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 10:20 AM

AbbVie Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 10:20 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: William J. Chase, Chief Financial Officer and Executive Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:US $59.06 USD -0.39

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $144.01 USD +1.99
AstraZeneca PLC 4,579 GBp +42.00
Bristol-Myers Squibb Co $51.51 USD +0.39
Eli Lilly & Co $66.53 USD -0.06
Novo Nordisk A/S kr281.70 DKK +0.10
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 23.0x
Price/Sales 4.9x
Price/Book 18.1x
Price/Cash Flow 22.7x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.